thymidine has been researched along with HIV in 92 studies
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Novel derivatives of the anti-HIV-1 agent, TSAO-T, bearing at the N-3 position alkylating groups or photoaffinity labels were prepared and evaluated for their anti-HIV activity." | 7.74 | Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation. ( Balzarini, J; Bonache, MC; Camarasa, MJ; Pérez-Pérez, MJ; Quesada, E; San-Félix, A; Sheen, CW; Sluis-Cremer, N, 2008) |
| "To evaluate whether an inter-individual variability in the activity of thymidine kinase (TK) and deoxycytidine kinase (dCK), which are involved in the first step of phosphorylation of some nucleoside analogues, exists in antiretroviral-naive, HIV-seropositive patients." | 7.73 | Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. ( Antonelli, G; Antonelli, L; Butera, O; Gianotti, N; Girardi, E; Iaiani, G; Lazzarin, A; Mazzi, R; Parisi, SG; Turriziani, O, 2005) |
| "The novel 5-chloro-, 5-bromo-, and 5-iodo-derivatives of 3'-fluoro-2',3'-dideoxyuridine (FddUrd), designated FddCIUrd, FddBrUrd, and FddIUrd, respectively, have been synthesized and evaluated for their antiretrovirus activity against human immunodeficiency virus (HIV) and murine Moloney sarcoma virus." | 7.67 | 5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine. ( Baba, M; Balzarini, J; De Clercq, E; Herdewijn, P; Pauwels, R; Schols, D; Van Aerschot, A, 1989) |
| "The effect of 3'-azido-2',3'-dideoxythymidine (AZT) on the human immunodeficiency virus (HIV)-associated giant cell formation was studied in vitro." | 7.67 | Effect of 3'-azido-2',3'-dideoxythymidine (AZT) and neutralizing antibody on human immunodeficiency virus (HIV)-induced cytopathic effects: implication of giant cell formation for the spread of virus in vivo. ( Kobayashi, N; Matsuda, A; Nakashima, H; Tochikura, T; Ueda, T; Yamamoto, N, 1987) |
| "Six HIV-antigenaemic patients with AIDS or AIDS-related complex were studied to assess the effect of treatment with low-dose zidovudine (250 mg) in 6-hourly doses on HIV antigen (HIV-Ag) levels in cerebrospinal fluid (CSF)." | 7.67 | Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. ( Cload, P; Danner, SA; de Gans, J; de Wolf, F; Derix, MM; Eeftinck Schattenkerk, JK; Goudsmit, J; Lange, JM; Ongerboer de Visser, BW, 1988) |
| "Among 16 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex studied serially, 12 had or developed antigenemia ranging from 16 to 3006 pg/mL in plasma." | 6.66 | Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). ( Despotes, JC; Emeson, EE; Falk, LA; Jackson, GG; Knigge, M; Mack, D; Paul, DA; Rubenis, M, 1988) |
| "18 men with longstanding human immunodeficiency virus (HIV) antigenaemia but no symptoms received zidovudine in low-dose regimens (250 mg 6-hourly, 500 mg 6-hourly, or 500 mg 12-hourly) with or without acyclovir." | 5.06 | Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. ( Cload, P; Coutinho, RA; de Gans, J; de Wolf, F; Fiddian, AP; Goudsmit, J; Lange, JM; Schellekens, PT; van der Noordaa, J, 1988) |
| "During zidovudine and stavudine treatment, HIV-1 selects several mutations (thymidine-associated mutations, TAMs) in the reverse transcriptase gene that confer high- and moderate-levels of resistance, respectively, to these nucleoside reverse transcriptase inhibitors (NRTIs)." | 4.82 | Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). ( Goldschmidt, V; Marquet, R, 2004) |
| "Zidovudine is a potent in vitro inhibitor of human immunodeficiency virus (HIV) with varying efficacy against other retroviruses." | 4.77 | Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. ( Barry, DW; Furman, PA, 1988) |
| "Novel derivatives of the anti-HIV-1 agent, TSAO-T, bearing at the N-3 position alkylating groups or photoaffinity labels were prepared and evaluated for their anti-HIV activity." | 3.74 | Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation. ( Balzarini, J; Bonache, MC; Camarasa, MJ; Pérez-Pérez, MJ; Quesada, E; San-Félix, A; Sheen, CW; Sluis-Cremer, N, 2008) |
| "To evaluate whether an inter-individual variability in the activity of thymidine kinase (TK) and deoxycytidine kinase (dCK), which are involved in the first step of phosphorylation of some nucleoside analogues, exists in antiretroviral-naive, HIV-seropositive patients." | 3.73 | Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. ( Antonelli, G; Antonelli, L; Butera, O; Gianotti, N; Girardi, E; Iaiani, G; Lazzarin, A; Mazzi, R; Parisi, SG; Turriziani, O, 2005) |
| "Oxygen-sulfur exchange at the C-4 carbonyl of several modified pyrimidine nucleosides, including 3'-azido-3'-deoxythymidine (AZT), is described in an effort to enhance the lipophilicity and, thereby, the delivery to the central nervous system of the sulfur analogues without compromising the anti-HIV activities of the parental structures." | 3.68 | Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders. ( Horwitz, JP; Kessel, D; Meltsner, BR; Palomino, E, 1990) |
| " Neither 3'-isocyano-3'-deoxythymidine (11) nor 3'-isocyano-2',3'-dideoxyuridine (12) showed anti-HIV activity at noncytotoxic concentrations." | 3.68 | Synthesis, antiretrovirus effects, and phosphorylation kinetics of 3'-isocyano-3'-deoxythymidine and 3'-isocyano-2',3'-dideoxyuridine. ( Balzarini, J; De Clercq, E; Hiebl, J; Zbiral, E, 1990) |
| "The thymidine analog 3'-azido-3'-deoxythymidine (BW A509U, azidothymidine) can inhibit human immunodeficiency virus (HIV) replication effectively in the 50-500 nM range [Mitsuya, H." | 3.67 | Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. ( Bolognesi, DP; Broder, S; Freeman, GA; Furman, PA; Fyfe, JA; Lehrman, SN; Mitsuya, H; Rideout, JL; St Clair, MH; Weinhold, K, 1986) |
| "The ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) and 3'-azido-3'-deoxythymidine (AZT) to inhibit human immunodeficiency virus (HIV) in the U-937 monocytic cell line was examined." | 3.67 | Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro. ( Gillis, JM; Hammer, SM, 1987) |
| "The novel 5-chloro-, 5-bromo-, and 5-iodo-derivatives of 3'-fluoro-2',3'-dideoxyuridine (FddUrd), designated FddCIUrd, FddBrUrd, and FddIUrd, respectively, have been synthesized and evaluated for their antiretrovirus activity against human immunodeficiency virus (HIV) and murine Moloney sarcoma virus." | 3.67 | 5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine. ( Baba, M; Balzarini, J; De Clercq, E; Herdewijn, P; Pauwels, R; Schols, D; Van Aerschot, A, 1989) |
| "The effect of D-penicillamine on the replication of the Human Immunodeficiency Virus (HIV) in H9 T-lymphoblastoid cells was evaluated." | 3.67 | Effect of D-penicillamine on the expression and propagation of the human immunodeficiency virus by H9 T-lymphoblastoid cells. ( Bitterlich, G; Dierich, MP; Hengster, P; Hofbauer, J; Larcher, C; Myones, BL; Schulz, TF; Sölder, B; Wachter, H, 1989) |
| "The 3'-fluoro-and 3'-azido-substituted derivatives of 2',3'-dideoxythymidine (ddThd), 2',3'-dideoxyuridine (ddUrd), 2',3'-dideoxy-5-ethyluridine (ddEtUrd) and 2',3'-dideoxycytidine (ddCyd) have been synthesized and evaluated for their anti-retrovirus activity [against human immunodeficiency virus (HIV) and murine Moloney sarcoma virus (MSV)]." | 3.67 | Anti-retrovirus activity of 3'-fluoro- and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues. ( Baba, M; Balzarini, J; De Clerq, E; Herdewijn, P; Pauwels, R, 1988) |
| "'Ampligen', a non-toxic, mismatched polymer of double-stranded RNA with antiviral and immunomodulatory activities reduced the concentration of zidovudine (azidothymidine, AZT; 'Retrovir', Wellcome) required for inhibitory activity against human immunodeficiency virus (HIV) in vitro." | 3.67 | Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. ( Carter, WA; Mitchell, WM; Montefiori, DC; Robinson, WE; Strayer, DR, 1987) |
| "Five dose regimens of 2',3'-dideoxycytidine (ddC) were administered, intravenously for 2 weeks then orally for 4 or more weeks, to 20 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC)." | 3.67 | Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). ( Allain, JP; Dubinsky, R; Fischl, MA; Klecker, RW; McAtee, N; McNeely, MC; Perno, CF; Thomas, RV; Wills, RJ; Yarchoan, R, 1988) |
| "In a study of treatment by zidovudine in 106 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex, an acute meningo-encephalitic illness developed in 4 of 21 patients within 17 days after the dose of zidovudine had had to be reduced because of myelotoxicity." | 3.67 | Acute meningo-encephalitis on dose reduction of zidovudine. ( Forster, S; Helbert, M; Jeffries, D; Kocsis, A; Peddle, B; Pinching, AJ; Robinson, D, 1988) |
| "2',3'-Dideoxythymidine (ddThd) and its 2',3'-unsaturated derivative 2',3'-dideoxythymidinene (ddeThd) are potent and selective inhibitors of human immunodeficiency virus (HIV) in vitro." | 3.67 | Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. ( Baba, M; De Clercq, E; Desmyter, J; Herdewijn, P; Pauwels, R; Vandeputte, M, 1987) |
| "The effect of 3'-azido-2',3'-dideoxythymidine (AZT) on the human immunodeficiency virus (HIV)-associated giant cell formation was studied in vitro." | 3.67 | Effect of 3'-azido-2',3'-dideoxythymidine (AZT) and neutralizing antibody on human immunodeficiency virus (HIV)-induced cytopathic effects: implication of giant cell formation for the spread of virus in vivo. ( Kobayashi, N; Matsuda, A; Nakashima, H; Tochikura, T; Ueda, T; Yamamoto, N, 1987) |
| "The effect of 3'-azido-3'-deoxythymidine (AZT) on replication of human immunodeficiency virus (HIV) in various hematopoietic cell lines was investigated." | 3.67 | Suppression of human immunodeficiency virus replication by 3'-azido-3'-deoxythymidine in various human hematopoietic cell lines in vitro: augmentation of the effect by lentinan. ( Kaneko, Y; Kobayashi, N; Nakashima, H; Tochikura, TS; Yamamoto, N, 1987) |
| "Six HIV-antigenaemic patients with AIDS or AIDS-related complex were studied to assess the effect of treatment with low-dose zidovudine (250 mg) in 6-hourly doses on HIV antigen (HIV-Ag) levels in cerebrospinal fluid (CSF)." | 3.67 | Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. ( Cload, P; Danner, SA; de Gans, J; de Wolf, F; Derix, MM; Eeftinck Schattenkerk, JK; Goudsmit, J; Lange, JM; Ongerboer de Visser, BW, 1988) |
| "Among 16 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex studied serially, 12 had or developed antigenemia ranging from 16 to 3006 pg/mL in plasma." | 2.66 | Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). ( Despotes, JC; Emeson, EE; Falk, LA; Jackson, GG; Knigge, M; Mack, D; Paul, DA; Rubenis, M, 1988) |
| "In patients not requiring HAART, treatment of hepatitis B should preferably consist of drugs without activity against HIV, such as pegylated interferon or adefovir." | 2.44 | [Hepatitis B in patients with HIV infection]. ( Barreiro, P; García-Samaniego, J; Martín-Carbonero, L, 2008) |
| "Patients with the acquired immunodeficiency syndrome (AIDS) die of overwhelming infections as a consequence of the destruction of the T4 subset of lymphocytes." | 2.37 | Developmental therapeutics and the acquired immunodeficiency syndrome. ( Broder, S; Chabner, BA; DeVita, VT; Fauci, AS; Kovacs, JA, 1987) |
| " At concentrations of up to 50 microM no natural 2'-deoxynucleosides, including thymidine, were able to reverse the toxic effects of AZT." | 1.27 | Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. ( Carlisle, R; Schinazi, RF; Sommadossi, JP; Zhou, Z, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 71 (77.17) | 18.7374 |
| 1990's | 9 (9.78) | 18.2507 |
| 2000's | 10 (10.87) | 29.6817 |
| 2010's | 2 (2.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palomino, E | 1 |
| Meltsner, BR | 1 |
| Kessel, D | 1 |
| Horwitz, JP | 1 |
| Herdewijn, P | 8 |
| Balzarini, J | 11 |
| De Clercq, E | 10 |
| Pauwels, R | 7 |
| Baba, M | 6 |
| Broder, S | 12 |
| Vanderhaeghe, H | 2 |
| Sigaloff, KC | 1 |
| Kayiwa, J | 1 |
| Musiime, V | 1 |
| Calis, JC | 1 |
| Kaudha, E | 1 |
| Mukuye, A | 1 |
| Matama, C | 1 |
| Nankya, I | 1 |
| Nakatudde, L | 1 |
| Dekker, JT | 1 |
| Hamers, RL | 1 |
| Mugyenyi, P | 1 |
| Rinke De Wit, TF | 1 |
| Kityo, C | 1 |
| Barreiro, P | 2 |
| Martín-Carbonero, L | 1 |
| García-Samaniego, J | 1 |
| López Bernaldo de Quirós, JC | 1 |
| Gaynor, JW | 1 |
| Cosstick, R | 1 |
| de Mendoza, C | 1 |
| Paxinos, E | 1 |
| Camino, N | 1 |
| Núñez, M | 1 |
| Soriano, V | 1 |
| Calvo, KC | 1 |
| Wang, X | 1 |
| Koser, GF | 1 |
| Goldschmidt, V | 1 |
| Marquet, R | 1 |
| Ross, L | 1 |
| Parkin, N | 1 |
| Chappey, C | 1 |
| Fisher, R | 1 |
| Clair, MS | 1 |
| Bates, M | 1 |
| Tisdale, M | 1 |
| Lanier, ER | 1 |
| Turriziani, O | 1 |
| Butera, O | 1 |
| Gianotti, N | 1 |
| Parisi, SG | 1 |
| Mazzi, R | 1 |
| Girardi, E | 1 |
| Iaiani, G | 1 |
| Antonelli, L | 1 |
| Lazzarin, A | 1 |
| Antonelli, G | 1 |
| Wirden, M | 1 |
| Malet, I | 1 |
| Derache, A | 1 |
| Marcelin, AG | 1 |
| Roquebert, B | 1 |
| Simon, A | 1 |
| Kirstetter, M | 1 |
| Joubert, LM | 1 |
| Katlama, C | 1 |
| Calvez, V | 1 |
| Park, AY | 1 |
| Moon, HR | 1 |
| Kim, KR | 1 |
| Chun, MW | 1 |
| Jeong, LS | 1 |
| Bonache, MC | 1 |
| Quesada, E | 1 |
| Sheen, CW | 1 |
| Sluis-Cremer, N | 1 |
| Pérez-Pérez, MJ | 1 |
| Camarasa, MJ | 1 |
| San-Félix, A | 1 |
| Xu, ZQ | 1 |
| Qiu, YL | 1 |
| Chokekijchai, S | 1 |
| Mitsuya, H | 5 |
| Zemlicka, J | 1 |
| Bochkarev, AV | 1 |
| Zavgorodniĭ, SG | 1 |
| Zhdanov, AS | 1 |
| Gurskaia, GV | 1 |
| Chen, MS | 2 |
| Suttmann, RT | 1 |
| Wu, JC | 1 |
| Prisbe, EJ | 1 |
| Almer, H | 1 |
| Classon, B | 1 |
| Samuelsson, B | 1 |
| Kvarnström, I | 1 |
| Yuzhakov, AA | 1 |
| Chidgeavadze, ZG | 1 |
| Beabealash-villi, RS | 1 |
| Hiebl, J | 1 |
| Zbiral, E | 1 |
| Wigerinck, P | 1 |
| Van Aerschot, A | 2 |
| Janssen, G | 1 |
| Claes, P | 1 |
| Camerman, N | 1 |
| Mastropaolo, D | 1 |
| Camerman, A | 1 |
| Furman, PA | 3 |
| Fyfe, JA | 3 |
| St Clair, MH | 1 |
| Weinhold, K | 1 |
| Rideout, JL | 2 |
| Freeman, GA | 2 |
| Lehrman, SN | 1 |
| Bolognesi, DP | 1 |
| Vogt, M | 1 |
| Schooley, RT | 4 |
| Hirsch, MS | 6 |
| Nakashima, H | 6 |
| Matsui, T | 2 |
| Harada, S | 2 |
| Kobayashi, N | 3 |
| Matsuda, A | 3 |
| Ueda, T | 3 |
| Yamamoto, N | 8 |
| Vogt, MW | 3 |
| Hartshorn, KL | 2 |
| Chou, TC | 3 |
| Coleman, LA | 2 |
| Crumpacker, C | 1 |
| DeVita, VT | 1 |
| Fauci, AS | 1 |
| Kovacs, JA | 1 |
| Chabner, BA | 1 |
| Kaplan, JC | 3 |
| Ueno, R | 3 |
| Kuno, S | 3 |
| Herzyk, P | 1 |
| Beveridge, A | 1 |
| Neidle, S | 1 |
| Berenbaum, MC | 1 |
| Lin, TS | 3 |
| Schinazi, RF | 3 |
| Prusoff, WH | 3 |
| Hammer, SM | 1 |
| Gillis, JM | 1 |
| Smith, MS | 1 |
| Brian, EL | 1 |
| Pagano, JS | 2 |
| Looney, DJ | 1 |
| Wong-Staal, F | 1 |
| Webb, TR | 1 |
| Majumdar, C | 1 |
| Abbotts, J | 1 |
| Wilson, SH | 1 |
| Mansuri, MM | 1 |
| Starrett, JE | 1 |
| Ghazzouli, I | 1 |
| Hitchcock, MJ | 1 |
| Sterzycki, RZ | 1 |
| Brankovan, V | 1 |
| August, EM | 1 |
| Sommadossi, JP | 2 |
| Schols, D | 1 |
| Bitterlich, G | 1 |
| Larcher, C | 1 |
| Sölder, B | 1 |
| Hengster, P | 1 |
| Myones, BL | 1 |
| Hofbauer, J | 1 |
| Schulz, TF | 1 |
| Wachter, H | 1 |
| Dierich, MP | 1 |
| Desmyter, J | 2 |
| Goubau, P | 1 |
| Vandeputte, M | 2 |
| Richman, DD | 2 |
| Kornbluth, RS | 1 |
| Carson, DA | 1 |
| Cooney, DA | 1 |
| Dalal, M | 1 |
| Kang, GJ | 1 |
| Cupp, JE | 1 |
| DeClercq, E | 1 |
| Johns, DG | 2 |
| Lin, JC | 1 |
| Zhang, ZX | 1 |
| Smith, MC | 1 |
| Biron, K | 1 |
| De Clerq, E | 1 |
| Yarchoan, R | 3 |
| Durno, AG | 1 |
| Paradis, TJ | 1 |
| Agyei-Aye, K | 1 |
| Baker, DC | 1 |
| Mitchell, WM | 1 |
| Montefiori, DC | 1 |
| Robinson, WE | 1 |
| Strayer, DR | 1 |
| Carter, WA | 1 |
| Perno, CF | 1 |
| Thomas, RV | 1 |
| Klecker, RW | 1 |
| Allain, JP | 2 |
| Wills, RJ | 1 |
| McAtee, N | 1 |
| Fischl, MA | 1 |
| Dubinsky, R | 1 |
| McNeely, MC | 1 |
| de Wolf, F | 2 |
| Lange, JM | 3 |
| Goudsmit, J | 3 |
| Cload, P | 2 |
| de Gans, J | 3 |
| Schellekens, PT | 1 |
| Coutinho, RA | 1 |
| Fiddian, AP | 1 |
| van der Noordaa, J | 1 |
| Reiss, P | 1 |
| Boucher, CA | 1 |
| Danner, SA | 2 |
| Fleury, HJ | 1 |
| Morere, G | 1 |
| Delord, B | 1 |
| Faivre, R | 1 |
| Helbert, M | 1 |
| Robinson, D | 1 |
| Peddle, B | 1 |
| Forster, S | 1 |
| Kocsis, A | 1 |
| Jeffries, D | 1 |
| Pinching, AJ | 1 |
| Steel, M | 1 |
| Tiessens, G | 1 |
| Portegies, P | 1 |
| Weber, J | 1 |
| Cardin, AD | 1 |
| Bowlin, TL | 1 |
| Krstenansky, JL | 1 |
| Kinney-Thomas, E | 1 |
| Hamamoto, Y | 1 |
| Barry, DW | 1 |
| Tochikura, T | 1 |
| Tochikura, TS | 1 |
| Kaneko, Y | 1 |
| Ikuta, K | 2 |
| Imai, H | 2 |
| Ueda, S | 2 |
| Suehiro, S | 2 |
| Kato, S | 2 |
| Jackson, GG | 1 |
| Paul, DA | 1 |
| Falk, LA | 1 |
| Rubenis, M | 1 |
| Despotes, JC | 1 |
| Mack, D | 1 |
| Knigge, M | 1 |
| Emeson, EE | 1 |
| Derix, MM | 1 |
| Eeftinck Schattenkerk, JK | 1 |
| Ongerboer de Visser, BW | 1 |
| Lefrere, JJ | 1 |
| Courouce, AM | 1 |
| Salmon, C | 1 |
| Permin, H | 1 |
| Dickmeiss, E | 1 |
| Petersen, CS | 1 |
| Ersbøll, J | 1 |
| Mathiesen, L | 1 |
| Krebs, HJ | 1 |
| Glaser, V | 1 |
| Matthes, E | 1 |
| Lehmann, C | 1 |
| Scholz, D | 1 |
| Rosenthal, HA | 1 |
| Langen, P | 1 |
| Torrence, PF | 1 |
| Kinjo, J | 1 |
| Lesiak, K | 1 |
| Carlisle, R | 1 |
| Zhou, Z | 1 |
| Barnes, DM | 1 |
| Chaisson, RE | 1 |
| Leuther, M | 1 |
| Volberding, PA | 1 |
| Blumberg, RS | 1 |
| Byington, R | 1 |
| Ito, M | 1 |
| Shigeta, S | 1 |
| Jablon, L | 1 |
| Lyerly, HK | 1 |
| Cohen, OJ | 1 |
| Weinhold, KJ | 1 |
| Gallo, RC | 1 |
| Elwell, LP | 1 |
| Ferone, R | 1 |
| Hill, JA | 1 |
| Ray, PH | 1 |
| Richards, CA | 1 |
| Singer, SC | 1 |
| Knick, VB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV[NCT00471614] | Phase 2 | 3 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine[NCT00001267] | Phase 3 | 42 participants | Interventional | 1990-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for thymidine and HIV
| Article | Year |
|---|---|
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deox | 2008 |
[Tenofovir DF in rescue regimens].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Clinical Trials, Phase III as Topic; Drug Resistance, Mul | 2008 |
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
Topics: Adenosine Triphosphate; DNA Primers; Drug Resistance, Multiple, Viral; Foscarnet; HIV; HIV Reverse T | 2004 |
Developmental therapeutics and the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Deoxyribonucleosides; HIV; Humans; Interferons | 1987 |
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoace | 1987 |
Spectrum of antiviral activity and mechanism of action of zidovudine. An overview.
Topics: Animals; Antiviral Agents; HIV; Humans; Retroviridae; Thymidine; Virus Replication; Zidovudine | 1988 |
Treatment of human immunodeficiency virus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; HIV; Humans; Ribavi | 1987 |
Strategies for the future chemotherapy of human immunodeficiency virus (HIV).
Topics: Acquired Immunodeficiency Syndrome; Drug Evaluation; HIV; Humans; Thymidine; Zidovudine | 1987 |
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report.
Topics: Acquired Immunodeficiency Syndrome; HIV; Humans; Structure-Activity Relationship; Thymidine; Zidovud | 1987 |
4 trials available for thymidine and HIV
| Article | Year |
|---|---|
[Chemotherapy and immunoprophylaxis of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Huma | 1986 |
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antigens, Viral; Antiviral Agents; Double-Blind Metho | 1988 |
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antigens, Viral; Antiviral Agents; Clinica | 1988 |
"On the shelf" AIDS drug in clinical trial.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Fusidic Acid; HIV; Humans; Thymidine; | 1987 |
79 other studies available for thymidine and HIV
| Article | Year |
|---|---|
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
Topics: AIDS Dementia Complex; Animals; Antiviral Agents; Cell Line; Chemical Phenomena; Chemistry; Chemistr | 1990 |
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
Topics: Antiviral Agents; Cell Line; Chemical Phenomena; Chemistry; Cytopathogenic Effect, Viral; Deoxyribon | 1987 |
Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
Topics: Amino Acid Substitution; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Res | 2013 |
Dinucleotides containing 3'-S-phosphorothiolate linkages.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dinucleoside Phosphates; Endonucleases; Hepatitis B; He | 2011 |
Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; | 2004 |
Bis-ketol nucleoside triesters as prodrugs of the antiviral nucleoside triphosphate analogues of 3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine.
Topics: Anti-HIV Agents; Cell Line; Esters; HIV; Humans; Molecular Structure; Nucleosides; Prodrugs; Stavudi | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resis | 2004 |
Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine Kinase; Fema | 2005 |
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.
Topics: Amino Acid Substitution; Clone Cells; Genotype; HIV; HIV Infections; Humans; Mutation; Thymidine | 2005 |
Synthesis of novel L-N-MCd4T as a potent anti-HIV agent.
Topics: Anti-HIV Agents; Bridged Bicyclo Compounds; HIV; Humans; Lymphocytes; Microbial Sensitivity Tests; M | 2006 |
Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation.
Topics: Azides; Benzophenones; Cell Line; Drug Design; HIV; HIV Reverse Transcriptase; HIV-1; HIV-2; Protein | 2008 |
Unsaturated acyclic analogues of 2'-deoxyadenosine and thymidine containing fluorine: synthesis and biological activity.
Topics: Adenine; Animals; Antineoplastic Agents; Antiviral Agents; Cattle; Deoxyadenosines; HIV; Humans; Hyd | 1995 |
[X-ray structural study of 3'-O-methylthiomethylthymidine and 3'-O-methylsulfinylmethylthymidine--potential inhibitors of HIV].
Topics: Antiviral Agents; HIV; Nucleic Acid Conformation; Thymidine; X-Ray Diffraction | 1995 |
Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus.
Topics: Cell Line; DNA; HIV; Humans; Kinetics; Phosphorylation; Substrate Specificity; T-Lymphocytes; Thymid | 1992 |
Synthesis of a phosphonomethyl analogue of 3'-deoxy-3-fluorothymidine.
Topics: Antiviral Agents; Cells, Cultured; HIV; Humans; Thymidine | 1991 |
A new method of synthesis of 3'-mercapto-3'-deoxythymidine.
Topics: Antiviral Agents; Cell Line; HIV; Humans; T-Lymphocytes; Thymidine; Zidovudine | 1991 |
Synthesis, antiretrovirus effects, and phosphorylation kinetics of 3'-isocyano-3'-deoxythymidine and 3'-isocyano-2',3'-dideoxyuridine.
Topics: Antimetabolites; Antiviral Agents; Cell Survival; Chemical Phenomena; Chemistry; Dideoxynucleosides; | 1990 |
Synthesis and antiviral activity of 3'-heterocyclic substituted 3'-deoxythymidines.
Topics: Animals; Antiviral Agents; Cell Transformation, Viral; Cells, Cultured; Chemical Phenomena; Chemistr | 1990 |
Structure of the anti-human immunodeficiency virus agent 3'-fluoro-3'-deoxythymidine and electronic charge calculations for 3'-deoxythymidines.
Topics: Antiviral Agents; Dideoxynucleosides; HIV; Hydrogen Bonding; Molecular Conformation; Molecular Struc | 1990 |
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
Topics: Antiviral Agents; Cell Survival; HIV; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Phosphory | 1986 |
Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro.
Topics: Antigens, Viral; Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; HIV; HIV Antigens; Human | 1986 |
Ribavirin antagonizes the effect of azidothymidine on HIV replication.
Topics: Cell Line; HIV; Humans; Lymphocytes; Monocytes; Phosphorylation; Phytohemagglutinins; Ribavirin; Rib | 1987 |
Antiviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus; DNA, Viral; Drug R | 1987 |
Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine.
Topics: Antiviral Agents; Dextran Sulfate; Dextrans; Drug Synergism; HIV; Humans; Thymidine; Zidovudine | 1987 |
Conformational properties of 3'-azido-3'deoxy-thymidine (AZT), an inhibitor of HIV reverse transcriptase.
Topics: Antiviral Agents; HIV; Models, Molecular; Molecular Conformation; Reverse Transcriptase Inhibitors; | 1987 |
Anti-HIV synergy between dextran sulphate and zidovudine.
Topics: Dextran Sulfate; Dextrans; Drug Synergism; HIV; Thymidine; Zidovudine | 1987 |
Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus.
Topics: Antiviral Agents; Deoxycytidine; HIV; Humans; Monocytes; Retroviridae Proteins; RNA-Directed DNA Pol | 1987 |
Anti-HIV synergism between dextran sulphate and zidovudine.
Topics: Antiviral Agents; Dextran Sulfate; Dextrans; Drug Synergism; HIV; Humans; Thymidine; Zidovudine | 1987 |
Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.
Topics: Antiviral Agents; Cell Line; Drug Synergism; Fluorescent Antibody Technique; HIV; Humans; Interleuki | 1987 |
Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine.
Topics: Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; DNA, Viral; Drug Resistance, Microbial; H | 1987 |
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells.
Topics: Antigens, Differentiation, T-Lymphocyte; Cell Line; Dextran Sulfate; Dextrans; Dideoxynucleosides; D | 1988 |
1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus.
Topics: Ancitabine; Chemical Phenomena; Chemistry; Cytarabine; Cytidine; HIV; Magnetic Resonance Spectroscop | 1988 |
Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition.
Topics: Algorithms; DNA Replication; DNA-Directed DNA Polymerase; HIV; Kinetics; Poly C; Poly T; Polynucleot | 1988 |
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.
Topics: Antiviral Agents; Bone Marrow; Dideoxynucleosides; HIV; Stavudine; Thymidine; Zidovudine | 1989 |
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Deoxyribonucleotides; Dideoxynuc | 1989 |
5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine.
Topics: Antiviral Agents; Cell Transformation, Viral; Deoxycytidine; Dideoxynucleosides; Halogens; HIV; Phos | 1989 |
Effect of D-penicillamine on the expression and propagation of the human immunodeficiency virus by H9 T-lymphoblastoid cells.
Topics: Cells, Cultured; HIV; HIV Antigens; Humans; Penicillamine; Spectrometry, Fluorescence; T-Lymphocytes | 1989 |
Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus.
Topics: Antigens, Viral; Antiviral Agents; Cell Line; Cell Survival; Cytopathogenic Effect, Viral; Deoxycyti | 1987 |
Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages.
Topics: Adenosine Kinase; Cell Line; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dideoxyadenosine; | 1987 |
2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.
Topics: Animals; Antiviral Agents; Deoxycytidine; Deoxycytosine Nucleotides; HIV; Humans; Leukemia L1210; Mi | 1987 |
The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.
Topics: Animals; Antiviral Agents; Cell Line; Deoxycytidine; HIV; Humans; Mice; Mice, Inbred C3H; Moloney mu | 1988 |
Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus.
Topics: Cell Line; Cytomegalovirus; Herpesvirus 3, Human; Herpesvirus 4, Human; HIV; Simplexvirus; Thymidine | 1988 |
Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro.
Topics: Cytopathogenic Effect, Viral; Deoxyadenosines; Deoxycytidine; Dideoxyadenosine; HIV; In Vitro Techni | 1988 |
Anti-retrovirus activity of 3'-fluoro- and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues.
Topics: Animals; Antimetabolites; Antiviral Agents; Cell Division; Deoxycytidine; Deoxycytidine Kinase; Dide | 1988 |
Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Cell Line; Deoxycytidine; Drug Synergism; HIV; Humans; Interferon Type I; Leukocyt | 1988 |
Synthesis and evaluation of a series of 1-(3-alkyl-2,3-dideoxy-alpha,beta-D-erythro-pentofuranosyl)thymines.
Topics: Acetylation; Chemical Phenomena; Chemistry; Chemistry, Physical; Chromatography, High Pressure Liqui | 1988 |
Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus.
Topics: Antiviral Agents; Cell Line; HIV; Humans; Poly I-C; Poly U; Polyribonucleotides; Thymidine; Virus Re | 1987 |
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Deoxycytidine; Drug Administration | 1988 |
Resumption of HIV antigen production during continuous zidovudine treatment.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; HIV; Humans; Thymidine; Zidov | 1988 |
Isolation of HIV from mononuclear cells of patients receiving zidovudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Antiviral Agents; HIV; Humans; Leuk | 1988 |
Acute meningo-encephalitis on dose reduction of zidovudine.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Complex; Antiviral Agents; Fo | 1988 |
IVth international AIDS conference.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Viral; Child; Congresses as Topic; Female; He | 1988 |
Acute meningoencephalitis on dose reduction of zidovudine.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; HIV; Humans; Meningoencephalitis; Thymidine; Viru | 1988 |
AIDS: the virus, antivirals and vaccines.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans | 1987 |
Inhibition of lymphocyte proliferation by synthetic peptides homologous to human plasma apolipoproteins B and E.
Topics: Apolipoproteins B; Apolipoproteins E; Binding Sites; Cell Division; Heparin; HIV; Humans; Lymphocyte | 1988 |
Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.
Topics: Antigens, Viral; Antiviral Agents; Cell Line; Cell Survival; Cytopathogenic Effect, Viral; Dideoxynu | 1987 |
Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro.
Topics: Antiviral Agents; Deoxycytidine; Fluorescence; HIV; Humans; In Vitro Techniques; Monocytes; Thymidin | 1987 |
Substances affecting the infection and replication of human immunodeficiency virus (HIV).
Topics: Cell Line; Cytopathogenic Effect, Viral; Deltaretrovirus; Dinoprostone; HIV; Humans; Interferon-gamm | 1986 |
Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus.
Topics: Antigens, Viral; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Dideoxynucleosides | 1987 |
Effect of 3'-azido-2',3'-dideoxythymidine (AZT) and neutralizing antibody on human immunodeficiency virus (HIV)-induced cytopathic effects: implication of giant cell formation for the spread of virus in vivo.
Topics: Antibodies, Viral; Antigens, Differentiation, T-Lymphocyte; Antigens, Surface; Antiviral Agents; Cel | 1987 |
Suppression of human immunodeficiency virus replication by 3'-azido-3'-deoxythymidine in various human hematopoietic cell lines in vitro: augmentation of the effect by lentinan.
Topics: Cell Line; Drug Synergism; Hematopoietic Stem Cells; HIV; Humans; Lentinan; Polysaccharides; T-Lymph | 1987 |
Amplification of human immuno-deficiency virus production from a virus-producing cell line in culture at high cell density.
Topics: Cell Line; Culture Media; Electrophoresis, Polyacrylamide Gel; HIV; Humans; Membrane Proteins; Thymi | 1987 |
Suppression by neurotropin of production of human immuno-deficiency virus by the virus-producing MOLT-4 cell line.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Surface; Antigens, Viral; Cell Line; HIV; Humans; Poly | 1987 |
Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Central Nervous System Diseases; HIV; HIV Antig | 1988 |
HIV antigenemia and zidovudine.
Topics: Antigens, Viral; Antiviral Agents; HIV; HIV Antigens; Humans; Thymidine; Zidovudine | 1988 |
[HIV infection and AIDS. Paris, 25-29 January 1988].
Topics: Acquired Immunodeficiency Syndrome; Antibody Formation; HIV; Humans; Thymidine; Zidovudine | 1988 |
[Zidovudin (Retrovir). A new antiviral agents against human immunodeficiency viruses (HIV)].
Topics: Antiviral Agents; Chemical Phenomena; Chemistry; HIV; Thymidine; Zidovudine | 1988 |
The effect of zidovudine on antigen levels in HIV infection.
Topics: Acyclovir; Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Antigens; HIV Sero | 1988 |
Phosphorylation, anti-HIV activity and cytotoxicity of 3'-fluorothymidine.
Topics: Animals; Antiviral Agents; Cell Division; Cell Line; Cell Survival; Cytidine Diphosphate; Cytopathog | 1988 |
AIDS dementia: synthesis and properties of a derivative of 3'-azido-3'-deoxythymidine (AZT) that may become 'locked' in the central nervous system.
Topics: Acquired Immunodeficiency Syndrome; Animals; Brain; Cell Line; Chemical Phenomena; Chemistry; Dement | 1988 |
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity.
Topics: Antiviral Agents; Cytidine; HIV; Humans; In Vitro Techniques; Macrophages; Stem Cells; Thymidine; Ur | 1988 |
Significant changes in HIV antigen level in the serum of patients treated with azidothymidine.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; HIV; HIV Antigens; Humans; Th | 1986 |
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.
Topics: Antiviral Agents; Drug Synergism; HIV; Humans; Interferon Type I; Recombinant Proteins; Thymidine; V | 1987 |
Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].
Topics: Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Interactions; Glycyrrhetinic Acid; G | 1987 |
Azidothymidine (AZT).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; HIV; Humans; Thymidine; Zidovudine | 1987 |
Transmission of HIV by antigen presenting cells during T-cell activation: prevention by 3'-azido-3'-deoxythymidine.
Topics: Antigen-Presenting Cells; Antiviral Agents; Cell Line; Cell Survival; HIV; Humans; Lymphocyte Activa | 1987 |
Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1.
Topics: Antiviral Agents; Cell Line; Drug Resistance, Microbial; HIV; Humans; T-Lymphocytes; Thymidine; Viru | 1987 |
The AIDS virus.
Topics: Acquired Immunodeficiency Syndrome; Animals; Chlorocebus aethiops; Genes, Viral; History, 20th Centu | 1987 |
Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U).
Topics: Antiviral Agents; DNA Replication; DNA, Bacterial; Drug Resistance, Microbial; Enterobacteriaceae; E | 1987 |